| Literature DB >> 32341701 |
Denis Anatolievich Putilin1, Sergey Yuryevich Evchenko2, Larisa Yaroslavivna Fedoniuk3, Olexandr Stepanovich Tokarskyy4, Oleksandr Mikhailovich Kamyshny5, Liudmyla Mikhailivna Migenko6, Serhiy Mikhailovich Andreychyn7, Iryna Ihorivna Hanberher7, Tetyana Oleksandrivna Bezruk8.
Abstract
The mammalian target of rapamycin is not only a central regulator of lipid metabolism that controls the processes of adipogenesis and lipolysis but also a regulator of the immunometabolism of immune cells that infiltrate adipose tissue. In turn, the level of progression of diabetes is significantly influenced by the Treg subpopulation, the complexity and heterogeneity of which is confirmed by the detection of numerous tissue-specific Tregs, including the so-called VAT Tregs (visceral adipose tissue CD4+Foxp3+ regulatory T cells). Therefore, the purpose of the study was to determine the mRNA expression levels of mTOR, Foxp3, IL1β, and IL17A genes in rat parapancreatic adipose tissue with experimental streptozotocin-induced diabetes mellitus, with or without metformin administration. The experiments were performed on male Wistar rats with induced diabetes as a result of streptozotocin administration. Molecular genetic studies were performed using real-time reverse transcription-polymerase chain reaction. The development of diabetes caused transcriptional activation of the mammalian target of rapamycin protein kinase gene, as well as increased mRNA expression of the pro-inflammatory cytokines IL1β and IL17A, but did not affect Foxp3 mRNA expression. The intervention with metformin in diabetic rats inhibited the mammalian target of rapamycin mRNA expression and caused an increase in the transcriptional activity of the Foxp3 gene in parapancreatic adipose tissue. ©Carol Davila University Press.Entities:
Keywords: Foxp3; IL17A; IL1β; adipose tissue; diabetes mellitus; mTOR; rat model; streptozotocin
Mesh:
Substances:
Year: 2020 PMID: 32341701 PMCID: PMC7175427 DOI: 10.25122/jml-2020-0029
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Specific primer pairs for amplification of the investigated and reference genes.
| Gene | Gene ID (NCBI-NLM database) | Primer | Tm,0 C | Product length (bp) | Exon junction |
|---|---|---|---|---|---|
| Foxp3 | NM_001108250.1 | F = TCTGGCCAAAAGACAGGTGG R = CTGTCCCAGGGTCCACAAAG | 60 | 40 | 2577/2578 |
| mTOR | NM_019906.1 | F = CGAGACTTGGAAGTCAGCCAC R = TCTGAGGCAGGCTGGATAACG | 60 | 61 | 214/215 |
| IL1β | NM_031512.2 | F = TCTTTGAAGAAGAGCCCGTCC R = GGTCGTCATCATCCCACGAG | 60 | 48 | 354/355 |
| IL17a | NM_001106897.1 | F = CTGGACTCTGAGCCGCAATG R = TGCCTCCCAGATCACAGAAG | 61 | 58 | 297/298 |
| GAP DH | F = GCCTGGAGAAACCTGCCAAG R = GCCTGCTTCACCACCTTCT | 61 | 52 | 825/826 |
Figure 1:Relative normalized mRNA number of mTOR genes (A), Foxp3 (B), IL1β (C) and IL17A (D) in PPAT. Normalization performed using the ΔΔCt method with GAPDH as the reference gene. C-control, d3, d5 – diabetic rats of 3 and 5 weeks, respectively.
Figure 2:Relative normalized mRNA number of mTOR genes(A-B), Foxp3 (C-D) in PPAT with or without metformin administration. Normalization performed using the ΔΔCt method with GAPDH as the reference gene. d3, d5 - diabetic rats of 3 and 5 weeks, respectively; d3+metformin, d5+metformin - diabetic rats of 3 and 5 weeks, respectively treated with metformin. Asterisk (*) indicates a significant difference (p < 0.05).